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Abstract

IMPACT OF FDAAA ON REGISTRATION, RESULTS REPORTING, AND
PUBLICATION OF CLINICAL TRIALS EVALUATING NEW
NEUROPSYCHIATRIC DRUGS APPROVED BETWEEN 2005 AND 2014

Constance X. Zou, Jessica E. Becker, Adam T. Phillips, James M. Garritano, Harlan M.
Krumholz, Jennifer E. Miller, Joseph S. Ross

Center for Outcome Research and Evaluation, Department of Medicine, Yale University
School of Medicine and Yale-New Haven Hospital, New Haven, Connecticut

Evidence-based medicine (EBM) promotes the use of randomized controlled trials
(RCTs) published in peer reviewed medical journals as the “gold standard”. However, up
to 50% of the completed clinical trials are never published and trials with results in favor
of studied interventions are 2-4 times more likely to have been published then those with
non favorable results. Publication bias seems to be a particularly severe problem for
RCTs evaluating newly approved brand-name neuropsychiatric drugs. Mandatory trial
registration, and later results reporting, were proposed to mitigate selective clinical trial
publication and outcome reporting. Congress enacted the FDA Amendments Act
(FDAAA) on September 27, 2007 requiring the registration of all non-phase I clinical
trials involving FDA-regulated medical interventions and results reporting for FDA
approved drugs. It’s been 10 years since FDAAA enactment, the impact of FDAAA on
the selective publication of clinical trials has not been studied. Our objective is to
determine whether FDAAA enactment is associated with improvements in trial
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registration and results reporting, as well as with decreased publication bias of clinical
trials evaluating new neuropsychiatric drugs. We conducted a retrospective cohort study
of all efficacy trials supporting FDA new drug approval between 2005 to 2014 for
neuropsychiatric indications. Trials were categorized as pre- or post-FDAAA based on
initiation and/or completion dates as outlined by the statue. The main outcomes were the
proportions of trials registered, proportions reported results in ClinicalTrials.gov, and the
degree of publication bias. Publication bias was estimated using the relative risks pre- and
post-FDAAA of both the publication of positive vs non-positive trials, as well as of
publishing positive vs. non-positive trials without misleading interpretations. Registration
and results reporting proportions were compared pre- and post-FDAAA using two-tailed
Fisher Exact Test and the degrees of publication bias were compared by calculating the
ratio of relative risks (RRR) for each period. Our study sample included 101 Pre-FDAAA
and 41 Post-FDAAA efficacy trials supporting the FDA approval of 37 new drugs for
neuropsychiatric indications between 2005 and 2014. Post-FDAAA trials were
significantly more likely to be registered (100% vs 64%; P<0.001) and report results
(100% vs 10%; P<0.001) than pre-FDAAA trials. Pre-FDAAA, positive trials were more
likely to be published (RR=1.52; 95% Confidence Interval [CI]=1.17-1.99; P=0.002) and
published without misleading interpretations (RR=2.47; Cl=1.57-3.73; p<0.001) than
those with non-positive results. In contrast, post-FDAAA positive trials were equally
likely to have been published (RR=1; Cl=1-1, p=NA), and published without misleading
interpretations (RR=1.20; Cl=0.84-1.72; p=0.30). The likelihood of publication bias preFDAAA vs. post-FDAAA was greater for publication of positive vs. non-positive trials
(RRR=1.52; Cl=1.16-1.99; p=0.002) and for publication without misleading
interpretations (RRR=2.06, Cl=1.17-3.61, p=0.01). The enactment of FDAAA was
followed by significantly higher proportions of trials that were registered and reported
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results on ClinicalTrials.gov, and with significantly lower degrees of publication bias
among trials supporting recent FDA approval of drugs for neuropsychiatric indications.

4
Acknowledgement

We would like to thank Dr. Vinay Rathi (Yale University School of Medicine Class of
2015) for his outstanding peer mentorship. We thank the organizers of the Eighth International Peer Review Congress (PRC) for giving us the opportunity to present our work,1
and the editors and reviewers who helped us publish our manuscripts in Trials.

1

Video recording of Ms. Zou’s presentation has been made available by the meeting or-

ganizer through Youtube. https://youtu.be/yDKwxE81Tk4

2

Zou CX, Becker JE, Phillips AT, et al. Registration, results reporting, and publication

bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after
FDAAA: a retrospective cohort study. Trials. 2018;19(1):581.

1

Table of Contents
INTRODUCTION ...........................................................................................................................1
The Role of Randomized Controlled Trials in Modern Medicine ....................................................1
RCT, Gold Standard with an Achille’s Heel. ...................................................................................2
RCT, Gold Standard or Gold Trojan Horse?.................................................................... ...............4
FDAAA: Mandatory Registration and Results Reporting ...............................................................5

STATEMENT OF PURPOSE .........................................................................................................7
METHOD ........................................................................................................................................9
Data Sources .....................................................................................................................................9
Novel Therapeutics Approved for Treating Neurological and Psychiatric Disorders, 2005-2014 ...9
Efficacy Trials Supporting FDA New Neuropsychiatric Drug Approval.......................................10
Determination of FDAAA Status ...................................................................................................11
Determination of Registration and Results Reporting Status on ClinicalTrials.gov ......................11
Determination of Publication Status ...............................................................................................12
Interpretation of Trial Results: Publication vs. FDA ......................................................................12
Validating the Published Interpretations .........................................................................................13
Calculating the Degree of Publication Bias ...................................................................................14
Data Collection and Data Validation .............................................................................................14
Data Analysis .................................................................................................................................15

RESULTS ......................................................................................................................................16
Characteristics of the Neuropsychiatric Drugs Approved between 2005-2014 ..............................16
Table 1. New Drug Applications (NDA) Approved by the FDA between 2005 and 2014 with
Indications for Neurologic and Psychiatric Conditions .................................................................16
Clinical Trials Supporting FDA Approval .....................................................................................18
Clinical Trial Registration and Results Reporting .........................................................................18
Publication and Published Interpretations .....................................................................................19
Table 2. Characteristics of 142 Efficacy Trials Supporting FDA Approval of NDA for
neuropsychiatric conditions, 2005-2014 .........................................................................................19
Table 3. Publication and Publication-FDA Agreement of Trials Supporting FDA Approval of
NDAs with Neuropsychiatric Indications with Positive, Equivocal, and Negative Results ...........20
Box 1 Examples of Trials Published with Interpretations Disagreeing with the Interpretations of
the FDA medical reviewers. ...........................................................................................................21
Publication Bias .............................................................................................................................25

DISCUSSION ................................................................................................................................26
Study Findings & Prior literature ....................................................................................................26
Implication for Understanding the Impact of FDAAA ...................................................................27
Implications for Future Policy Development ..................................................................................28
Implications for the Practice of Medicine .......................................................................................28
Limitations ......................................................................................................................................29
Conclusions ....................................................................................................................................30

2

REFERENCE.................................................................................................................................31
FIGURES, TITLES, AND LEGENDS..........................................................................................31
Figure 1. Identification of Trials Reviewed by the FDA for New Drug Applications with
Neuropsychiatric indications, 2005-2014 .......................................................................................37
Figure 2 Registration and Results Reporting Status of Trials Supporting FDA Indications by
FDAAA applicability, 2005-2014 ..................................................................................................38
Figure 3. Publication Status and Publication-FDA Agreement of Neuropsychiatric Trials by
FDAAA Applicability and by Trial Results ...................................................................................39

1

Introduction

The Role of Randomized Controlled Trials in Modern Medicine
Randomized controlled trials (RCT) started to have profound impacts on the practice of medicine today since the rise of evidence-based medicine (EBM) , which has been
defined as “the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients.” (1) However, it is difficult, to put
one’s finger on what made EBM the haute couture, based on its name and such a definition. Some find it difficult to distinguish the phrase EBM from the word medicine itself.
(2, 3) (3)(4–7)If one were to summarize the teaching of how-to-EBM textbooks and
guides(14–18), EBM method describes an RCT based formula to answer hypothetical
questions involving hypothetical patients with hypothetical diseases related to clinical
care. The main agenda of the EBM campaign is to make sure that RCTs are the best evidence and that only the RCT are good enough to rely on as the “gold standard” for
“judging whether a treatment does more good than harm” (19)because they are “so much
more likely to inform clinicians and so much less likely to mislead them” (than the alternatives).(20)(3)(21)
The success of EBM campaign has resulted in many parts of medicine being governed by RCTs through the Practice Guidelines, which are usually issued by medical professional societies outlining best practices. These practice guidelines are welcomed by
physicians who are believers of the power of RCT but find themselves incapacitated by
the complexity of the method and the volume of the work involved in full EBM style investigation and calculation. The proponents of EBM may object to the idea that EBM encourages mindless following of practice guidelines, after all, the physician can and should
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learn to speak the EBM fluently themselves and use it to guide their day to day practice.
That could happen if the United States suddenly required graduate degrees in statistics for
all medical school graduates; if the physicians have at least days between each appointment to perform one round of rituals in full as outlined by the 500-hundred page long
EBM bible; (21) and if there is a sudden change of US malpractice law. The truth is the
physicians cannot afford the time or the effort to perform EBM on their own. When they
do try, it usually means a quick PubMed search followed by skimming through the abstracts of a few randomly selected publications of RCTs. They could not afford the luxury sometimes to disobey the order of the “best practice” as outlined in the practice
guidelines, even when they have good reasons to believe it inappropriate for a given setting. They may lose bonuses tied to meeting “quality measures”, which are frequently
based on guidelines, or worse, they can be sued for transgressing the norm as definied by
their professional societies even though it was suppose to be a suggestion.
Practice guidelines are being used in the malpractice arena to define a credible standard
of care to measure the accused physician for an alleged problem addressed. This may
occur despite a medical society's disclaimer that they are not intended, nor devised, for
that purpose. (22)

RCT, Gold Standard with an Achille’s Heel
The EBM formula relies on RCTs published in the literature. The problem is as
many as 50% of completed clinical studies were never published (23–42)What’s more,
trials with non-positive results were significantly more likely to remain unpublished than
trials with positive results and negative results were often manipulated to appear positive.
(39, 43–46)
Experience has shown that such study reports do not always contain a complete, or entirely accurate, representation of study plans, conduct and outcomes. Outright fraud (i.e.,
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deliberate deception) is unusual. However, incompleteness, lack of clarity, unmentioned
deviation from prospectively planned analyses, or an inadequate description of how critical endpoint judgments or assessments were made are common flaws. (47)

Because studies were usually considered positive when whatever proposed new intervention works better than a control, publication bias leads to perceived efficacy. EBM
informed clinical practice based on half of the whole truth can result in inappropriate enthusiasms for what’s new. Many considered the problems of nonpublication and untruthful publication to be particularly severe among trials evaluating newly approved brand
name neuropsychiatric drugs.(48) Clinical studies supporting approved drugs for neuropsychiatric indications, such as paroxetine (Paxil) (49), reboxetine (Edronax )
(50)gabapentin (Neurontin) (51), and lamotrigine (Lamictal) (52), have been identified as
being subject to underreporting. Data demonstrating these drugs to be potentially ineffective for approved indications or suggesting harm were not publicly disclosed until the
pharmaceutical companies’ internal documents were reviewed during legal proceedings
(53, 54)
Ten years ago, if a psychiatrist were to use the EBM method to calculate and compare the effect size of any of the one dozen antidepressants approved in the previous several decades, he or she would find only good news—all of the published trials showed the
drugs to be effective, but in fact only half of the completed trials were. The physician
would overestimate the effect size of each drug for about 30%. (28)Take one of these antidepressants Serzone (nefazodone) for example, which was approved by the FDA in
1994. When the drug was just approved, Bristol-Myers called it a "significant" addition
to the numerous antidepressants with an “additional boost, fewer side-effects—and a
lower price.”(55) It was speculated that the sales of this drug contributed to the fact that
Bristol-Myers Squibb “posted record results for 1996.” (56) While its effective size based
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on FDA documents was only 0.26. Effect size measures the magnitude of difference between a given drug and the placebo. 0.2-0.5 is small difference, 0.5-0.8, medium, and
0.8-1, high. 0.26 means the difference between nefazodone and sugar pills are small. Because its effective size based on the published trials was 69% higher, EBM practice based
on published RCTs would conclude that the drug seem to have a moderate effect. (28) It
is also worth noting this drug was associated with severe liver toxicity and death and was
pulled from the market in 2004. (57–59)
Similarly, among trials evaluating drugs indicated for anxiety (23), and psychotic
disorders (60) that were first approved by the U.S. Food and Drug Administration (FDA)
in recent decades, 80-90% of trials with negative or equivocal results were either not published or were published in a misleading manner to suggest a positive result, while nearly
100% of trials with positive results were published.

RCT, Gold Standard or Gold Trojan Horse?
Many feel that this new paradigm brought by EBM based on RCT is doomed to fail
because the industry can and will harness the power of RCT for the benefit of the few. (2,
3, 61–73)
In the perfect world pictured by the proponents of EBM, RCTs are performed by
disinterested researchers who are driven only by the desire to further truth,to improve
care, and to reduce waste. In reality, most large RCT are sponsored by the industry as
business strategy. It is unrealistic to expect that they will always choose to protect the
public interest even at the cost of getting a smaller share of the $3 Trillion that United
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States spends on healthcare each year, of which 17% were for prescription drugs. (74)
Because of high cost of new drug development, high risk of failure, and high potential financial gain, conflicts of interest is a particularly serious problem for RCT evaluating new drugs. With few exceptions, for profit industry are the primary funders of clinical
trials because of the high cost associated with conducting early phase clinical trials to
evaluate drugs that had never been used in humans: Phase II trials can cost up to $20 million dollars, while Phase III, up to $50 million each. On average, the cost to run clinical
trials to support the FDA approval of a new drug for a single indications is about 200 millions dollars. In order for the drug company to profit, not only they need to recover the
astronomical cost invested in the drug targest that received approval, but also those that
did not, which happens 2 to 50 times more often. (75, 76) (77)

FDAAA: Mandatory Registration and Results Reporting
What can be done to prevent the results of completed trials from being swept under
the rug? Publication has always been and will likely remain voluntary, but if the protocols and results of all clinical trials can be found through a publicly accessible, centralized trial registry, it would be difficult for the sponsors to withhold trials with unfavorable results or to introduce post hoc analysis to encourage positive interpretations of the
results. Additionally, Journal editors, peer reviewers, and interested members of the public could cross reference the results submitted by the sponsors and investigators for publication.
In 1997, Congress passed the FDA Modernization Act (FDAMA), which mandated
the first U.S.-based public registry ClinicalTrials.gov in 2000 by the National Institute of
Health (NIH) . In 2005, the International Committee of Medical Journal Editors (ICMJE)
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issued a policy requiring trial registration as a condition of publication in member journals.De Angelis et al., 2009, #257} Nonetheless, FDAMA only required registration of a
small number of trials, while the ICMJE recommendation was only followed on a voluntary basis and still permitted publication of unregistered trials. (78) (79)
In 2007, Congress passed the FDA Amendments Act (FDAAA). At the time
FDAAA was applicable to essentially all non-phase I interventional studies involving
FDA-regulated drugs, biological products, or devices with manufacture site or trial site
based in the United States. FDAAA mandated that sponsors and investigators register all
applicable trials in ClinicalTrials.gov prior to subject enrollment, and report results to
ClinicalTrials.gov within 30 days post approval of the indication being studied. FDAAA
is applicable to trials that began after September 27th, 2007 and to earlier trials that were
still ongoing as of December 26th, 2007. Inappropriately delayed registration and results
reporting, as well as reporting of false results, are punishable by fines of up to $10,000
per day and can lead to withholding of funding from studies receiving federal support.
It has now been ten years since FDAAA was enacted. Its impact on clinical trial
registration, results reporting, and publication bias has largely remained undetermined.
(41)Recently we demonstrated that FDAAA was associated with increased registration
and publication of clinical studies in another study involving new drugs approved to treat
cardiovascular disease and diabetes (CXZ performed data validation and contributed to
the final editing of the manuscript for publication). (80)However, no study has focused
on trials involving drugs treating neurological and psychiatric conditions, an area for
which concern for selective publication and outcome reporting remain.
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Statement of Purpose

We conducted a retrospective cohort study using efficacy trials that were submitted
to and reviewed by the FDA for the approval of new drug applications (NDA) between
2005 and 2014 for the treatment of neurologic and psychiatric conditions. Our objective
is to compare the rate of registration, results reporting, and the degree of publication bias
for efficacy trials involving newly approved drugs treating neurologic and psychiatric
conditions before and after the enactment of FDAAA. For each trial, we determined
whether a trial is pre- or post-FDAAA based on trial initiation and/or completion dates,
as well as their registration, results reporting, and publication status, Prior to conducting
this study, we put forth the following hypotheses:

1.

There is an association between the FDAAA status, and the likelihood of trial
registration on ClinicalTrials.gov.

2.

There is an association between the FDAAA status, and the likelihood of trial
results reported to ClinicalTrials.gov.

3.

There is an association between the FDAAA status and the degree of publication bias.

The aim of this study was three fold: (1) to assess the impact of FDAAA on selective registration and publication of efficacy trials supporting new drugs approved by the FDA to
treat neurologic and psychiatric conditions, (2) to assess the degree of publication bias
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among trials evaluating newly approved neuropsychiatric drugs, and (3) to inform ongoing efforts to regulate clinical trials registration and results reporting.

9

Method

Data Sources
Data were obtained from three sources: Drugs@FDA , ClinicalTrials.gov and
PubMed’s listing of Medline-indexed journals. Drugs@FDA is a public database
maintained by the FDA, providing access to regulatory actions and documents issued for
each drug approved by the agency. ClinicalTrials.gov is a public clinical trial registry
database maintained by the National Library of Medicine at the NIH (U.S. National
Library of Medicine 2018). PubMed’s list of Medline-indexed journals includes more
than 5,500 biomedical journals.

Novel Therapeutics Approved for Treating Neurological and Psychiatric Disorders,
2005-2014
The Center of Drug Evaluation and Research (CDER), which is part of the FDA,
provides annual reports summarizing all New Drug Applications (NDAs) approved in
each year (U.S. Food and Drug Administration). We downloaded the reports from 2005
to 2014, when available, and otherwise searched Drugs@FDA for those NDAs that were
approved to treat neurologic and psychiatric disorders. Our study sample began with
drugs approved in 2005 to align with our prior work (Downing, Aminawung et al. 2014)
and because an earlier seminal study on the topic examined all antidepressants approved
through 2004 (Turner, Matthews et al. 2008); we chose to exclude drugs approved after
December 2014 to ensure that at least 24 months had passed between drug approval date
and the date when we concluded the final search for the registration record, reported
results and publication, which was March 2017. For each NDA, we recorded its
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indication, orphan status, priority review status, accelerated approval status, sponsor, and
approval date.
CXZ performed all of the above data collection in the summer of 2016. JSR, as the
principle investigator, reviewed with CXZ the lists of approved NMEs and BLAs
between 2005 and 2014 to ensure that all new drugs approved with neuropsychiatric
indications were included in our sample. JSB, randomly selected 4 drugs using an online
randomizer and validated the data collected for those 4 drugs.

Efficacy Trials Supporting FDA New Neuropsychiatric Drug Approval
As described in a comprehensive tutorial for how to use the Drugs@FDA (Turner
2013), we downloaded the relevant FDA files for each NDA from Drugs@FDA,
including the approval letters, summary reviews, clinical reviews, and statistical reviews.
Among these files, we searched for clinical trials evaluating the efficacy of the drugs
under review. We included only trials for which the FDA discussed and characterized
results, based on the assumption that these trials influenced the FDA’s decision to
approve the study drug for the proposed indication. We excluded ongoing trials, phase
I/safety-only trials, expanded access trials, terminated and withdrawn trials without
enrollment, and trials evaluating indications different than that for which the drugs were
originally approved. We also excluded failed trials. Failed trials were determined by the
FDA and the results of failed trials are invalid. For each included trial, we recorded the
following characteristics: pivotal status, phases, sponsors, study sites, trial length,
randomization, blinding, types of control, description of the treatments, arms of the
investigational drugs, enrollment numbers, and the primary efficacy endpoints. A pivotal
study is defined by the FDA as “a definitive study in which evidence is gathered to
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support the safety and effectiveness evaluation of the medical product for its intended
use” (2013). Pivotal status was frequently assigned prospectively by FDA, occasionally
assigned retrospectively by the FDA, or at times not assigned by FDA and thus
determined using a previously described method. (Downing, Aminawung et al. 2014) All
searches and data collection were done by CXZ between June 2015 and October 2015.
JSB validated the data collected associated with previously randomly selected 4 NDAs.

Determination of FDAAA Status
At the time when. FDAAA was enacted in 2007, it applied to trials that were
initiated after September 27th, 2007, as well as to trials initiated earlier but still ongoing
as of December 26th, 2007. Based on this, FDAAA applicable trials were categorized as
post-FDAAA, while trials that were initiated or completed prior to the cut-off dates were
categorized as pre-FDAAA. All coding was done by CXZ in the summer of 2015. JSB
validated the data collected associated with previously randomly selected 4 NDAs.

Determination of Registration and Results Reporting Status on ClinicalTrials.gov
To determine whether trials were registered and reported results on
ClinicalTrials.gov, one investigator (CXZ) performed the initial search using the
following terms and their combination: generic, or brand names of the study drugs, drug
indications, trial IDs, trial acronyms, numbers of participants randomized, comparators,
and study time frames. All searches were done by CXZ between the summer of 2015.
JSB validated the data collected associated with previously randomly selected 4 NDAs.
For trials that were not able to be matched with any registration record, a second
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investigator (JEB) independently performed a second round of searches. No new records
were identified.

Determination of Publication Status
To determine whether trials were published, we searched PubMed for full-length
publications using the same terms as we did for the registration record. Among identified
publications, abstracts and conference reports were excluded. Publications reporting
multiple trials, such as reviews and meta-analyses were also excluded unless the results
of each trial were analyzed and discussed individually in the level of detail as one would
expect from a full-length publication. When the search terms returned too many similar
entries in PubMed, we used Google Scholar to narrow the results. Google Scholar has the
advantage that it can search among the full texts of publications hosted by a variety of
online database or platforms, while for many journals, especially those that require paid
access, PubMed searches only among the title and abstracts. All searches were done by
CXZ between the summer of 2015 and the spring of 2016. JSB validated the data
collected associated with previously randomly selected 4 NDAs. For trials that were not
able to be matched with any registration record, a second investigator (JEB)
independently performed a second round of searches. No new records were identified.

Interpretation of Trial Results: Publication vs. FDA
Trials were classified as positive, negative, or equivocal based on the FDA’s
interpretation of the results as described in Additional File 1. The classification was
based on whether the primary outcome(s) achieved statistical significance while taking
into consideration the summary statements made by the FDA medical reviewers
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regarding whether or not the findings provide support for the efficacy claim of the study
drugs. Published trial results were categorized similarly based on whether the primary
outcomes achieved statistical significance according to the authors’ analysis while taking
into considerations the authors’ conclusions in the abstract section. Trials with equivocal
or negative results were grouped together as non-positive trials for purposes of
calculating publication bias.
All data collection was done by CXZ between the summer of 2015 and the spring
of 2016. JSB validated the data collected associated with previously randomly selected 4
NDAs. For trials that were not able to be matched with any registration record, a second
investigator (JEB) independently performed a second round of searches. No new records
were identified.

Validating the Published Interpretations
We validated the interpretations of the trial results made by the study
investigators for each publication using the interpretations made by the FDA medical
reviewers found in the FDA approval package as the gold standard. Both the conclusions
in the abstract and the main text of the publications were validated. The two were
considered in agreement if the interpretations were both categorized as positive, negative
or equivocal, and no major contradictions existed between the two statements. As an
example of contradiction between two sources: the published interpretation of trial 02 of
milnacipran (Savella) concluded that “both doses (100 and 200 mg/d) were associated with
significant improvements in pain and other symptoms.” (81) This was considered different from
the statement made by the FDA in the summary review documents, which stated that “[the]
analysis of the ‘pain only’ responders does not indicate that there is a significant effect of MLN
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(Savella) on pain….(treatment effect) was driven by the patient global response outcome rather
than the pain or function outcome…when studied in isolation, statistically significant treatment
effects for pain and function were not demonstrated.” (82) All coding was done by CXZ in the

summer and fall of 2016. JSB validated the coding associated with the previously
selected 4 drugs. Due to the interpretive nature of this comparison, two additional
investigators (JEB and JSR) reviewed all instances where there was disagreement
between the FDA’s and the authors’ interpretation.

Calculating the Degree of Publication Bias
We calculated and compared two different measures of publication bias between
pre- and post-FDAAA trials. First, we estimated the relative risk of publication of
positive vs non-positive trials in each period. Second, we estimated the relative risk of
publishing positive vs non-positive trials without misleading interpretations in each
period. Thus, publication bias was calculated as the ratio of relative risks (RRR) preFDAAA vs post-FDAAA. CXZ completed the data analysis in fall 2017 and JSR
performed validation of the analysis.

Data Collection and Data Validation
Registration status, results reporting status, publications status, and publicationFDA interpretation agreement were validated as described previously. We performed a
quality control for the rest of the data set, many of which were collected but not reported
for purposes of this study. A second investigator (JEB) re-collected all data elements
obtained for a random 10% sample of the included new drug approvals, using an online
randomization tool to randomly select 4 out of the 37 drugs. Among the 676 unique data
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elements collected by the two investigators, the rate of agreement was 99.6% and
disagreements were resolved through consensus.

Data Analysis
We used descriptive statistics to characterize the proportions of trials that were
registered and reporting results on ClinicalTrials.gov. We used two-tailed Fisher Exact
tests to compare the proportions among pre- and post-FDAAA trials. Analysis was
performed using Epi Info Companion App for iOS (3.1.1) (Centers for Disease Control
and Prevention [CDC]; Atlanta, GA) , as well as with MedCalc online statistical software
(2016), supplemented using an online program written by Hutchon (Hutchon 2015) to
calculate the RRRs to estimate both measures of publication bias.
All data analysis was completed by CXZ, JSR independently validated the analysis.
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Results

Characteristics of the Neuropsychiatric Drugs Approved between 2005-2014
Between January 1st, 2005 and December 31st, 2014, 37 new drugs were approved
by the FDA for the treatment of neuropsychiatric conditions, of which 23 (62%) were
approved for neurological conditions and 14 (38%) for psychiatric disorders, which
included 3 drugs for substance-use related conditions (Table 1). Among the 37 approved
drugs, 34 (92%) were pharmacologic therapies, 3 (8%) were biologics; orphan status was
granted for 9 (24%), priority review status for 6 (17%), and accelerated approval for 1
(3%)

Table 1. New Drug Applications (NDA) Approved by the FDA between 2005 and 2014
with Indications for Neurologic and Psychiatric Conditions.
Brand Name

INN Name

NDA Applicant

Indication

Rozerem

Ramelteon

Insomnia

Chantix

Varenicline
Tartrate
Rasagiline
Mesylate
Paliperidone

Takeda
Global
Pfizer

Approval
Year
2005

Smoking cessation

2006

Teva

Parkinson’s disease

2006

Janssen,
L.P.
New River

Schizophrenia

2006

Attention deficit hyperactivity disorder

2007

Azilect
Invega
Vyvanse
Neupro

Lisdexamfetamine Dimesylate
Rotigotine

Schwarz Bioscience
Wyeth

Parkinson’s disease

2007

Major depressive disorder

2008

Pristiq

Desvenlafaxine Succinate

Relistor

Methylnaltrexone Bromide

Progenics

Opioid-induced constipation

2008

Xenazine

Tetrabenazine

Prestwick

Huntington's disease

2008

Vimpat

Lacosamide

Schwarz Bioscience

Partial-onset seizure disorder

2008
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Banzel

Rufinamide

Eisai INC

Nucynta

Tapentadol
Hydrochloride

Lusedra

Fospropofol
Disodium
Milnacipran
Hydrochloride

Ortho
Mcneil
Janssen
Eisai Medical
Cypress Bioscience
INC
Ipsen Biopharm Limited
Vanda Pharmaceuticals
Inc
Organon
USA INC
Lundbeck
Inc

Savella
Dysport

Abobotulinumtoxina

Fanapt

Iloperidone

Saphris
Sabril

Asenapine
Maleate
Vigabatrin

Qutenza

Capsaicin

Ampyra

Dalfampridine

Xeomin

Incobotulinumtoxina

Gilenya

Fingolimod

Latuda

Lurasidone
Hydrochloride

Viibryd

Vilazodone
Hydrochloride

Horizant

Gabapentin
Enacarbil

Potiga

Ezogabine

Onfi

Clobazam

Aubagio

Teriflunomide

Fycompa

Perampanel

Sanofi
Aventis US
LLC
Eisai INC

Dotarem

Dimethyl
Fumarate

Biogen Idec
INC

Neurogesx
Inc
Acorda
Therapeutics Inc
Merz Pharmaceuticals
GMBH
Novartis
Pharmaceuticals Corp
Sunovion
Pharmaceutical INC
Trovis Pharmaceuticals
LLC
Glaxo
Group LTD
DBA GlaxoSmithKline
GlaxoSmithKline
Lundbeck
INC

Seizures associated with Lennox-Gastaut
syndrome
Acute Pain

2008

Anesthesia

2008

Fibromyalgia

2009

Cervical dystonia

2009

Schizophrenia

2009

Bipolar I disorder

2009

Complex partial seizure disorder

2009

Neuropathic pain

2009

Multiple sclerosis

2010

Cervical dystonia and Blepharospasm

2010

Multiple sclerosis

2010

Schizophrenia

2010

Major depressive disorder

2011

Restless legs syndrome

2011

Partial seizure disorder

2011

Seizures associated with Lennox-Gastaut
syndrome

2011

Multiple sclerosis

2012

Partial seizure disorder

2012

Multiple sclerosis

2013

2008
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Trintellix (formerly Brintellix)

Vortioxetine

Aptiom

Eslicarbazepine Acetate

Hetlioz

Tasimelteon

Northera

Droxidopa

Belsomra

Suvorexant
MK4305

Plegridy

Peginterferon
Beta-1A

Movantik

Naloxegol

Takeda
Pharmaceuticals USA
INC
Sunovion
Pharmaceuticals INC
Vanda Pharmaceuticals
Inc
Chelsea
Therapeutics Inc
Merck
Sharp and
Dohme
Corp
Biogen Idec
INC

Major depressive disorder

2013

Partial seizure disorder

2013

Non-24-hour sleep-wake disorder

2014

Neurogenic orthostatic hypotension

2014

Insomnia

2014

Multiple sclerosis

2014

Constipation s/p opioids

2014

Astrazeneca
Pharmaceuticals LP

Note: INN= International nonproprietary name; NDA=New Drug Application;
ADHD=Attention deficient hyperactivity disorder; please refer to the drug label for full
description of each drug indication.
Clinical Trials Supporting FDA Approval
There were 142 efficacy trials that supported the approval of these 37
neuropsychiatric drugs (Figure 1), of which 101 (71%) were categorized as pre-FDAAA
and 41 (29%) as post-FDAAA. All 142 trials were funded by industry and 105 (74%)
were phase III, 33 (23%) phase II, and 4 (3%) phase II/III. In addition, the results of 107
(75%) of the trials were interpreted by the FDA to be positive, 17 (12%) as equivocal,
and 18 (13%) as negative (Table 2).

Clinical Trial Registration and Results Reporting
FDAAA was followed by significantly greater proportions of trial registration and
results reporting. Pre-FDAAA, 64% (65 of 101) of clinical trials were registered on
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ClinicalTrials.gov, while 100% (41 of 41) of post-FDAAA trials were registered
(P<0.001; Figure 2). Similarly, pre-FDAAA, 10% (10 of 101) of clinical trials reported
results on ClinicalTrials.gov, while 100% (41 of 41) of post-FDAAA trials reported
results (P<0.001; Figure 2); the results of 32 of 41 (78%) FDAAA trials were reported
within 30 days of drug approval.

Publication and Published Interpretations
Pre-FDAAA, among 72 positive trials, none were unpublished nor published with
misleading interpretation. In contrast, among 29 non-positive trials, 10 (34%) were not
published and 7 (24%) were published with misleading interpretations. Post-FDAAA,
among 35 positive trials, again none were unpublished and none were published with a
misleading interpretation. In addition, among 6 non-positive trials, none were
unpublished and only 1 was published with a misleading interpretation. (Figure 3) The
publications of the following new drugs had misleading interpretations: Droxidopa
(Northera) of Chelsea Therapeutics, Dalfampridine (Ampyra) of Acorda Therapeutics,
Iloperidone (Fanapt) of Vanda Pharmaceuticals, Milnacipran Hydrochloride (Savella) of
Forest Research and Cypress Bioscience, and Rulfinamide (Banzel) of Novartis (Box 1).

Table 2. Characteristics of 142 Efficacy Trials Supporting FDA Approval of NDA for
Neuropsychiatric Conditions, 2005-2014.

No. (%)

No. Registered (%)

No. Results Reported (%)

No. Published (%)

65 (64%)

10 (10%)

91 (90%)

(n=142)
FDAAA Applicability
Pre-FDAAA

101 (71%)
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Post-FDAAA
41 (29%)
41 (100%) 41 (100%) 41 (100%)
Pivotal Status
Pivotal
92 (65%)
78 (85%)
40 (43%)
90 (98%)
Non-Pivotal
50 (35%)
28 (56%)
11 (22%)
8 (84%)
Study Location
All United States
65 (46%)
50 (77%)
14 (22%)
61 (94%)
Some United States
54 (38%)
41 (76%)
29 (54%)
48 (89%)
None United States
23 (16%)
15 (65%)
8 (35%)
23 (100%)
Study Phase
Phase II
33 (23%)
17 (52%)
7 (21%)
28 (85%)
Phase III
105 (74%) 87 (83%)
44 (42%)
102 (97%)
Phase II/III
4 (3%)
2 (50%)
0 (0%)
2 (50%)
Randomization
NA (single-group)
5 (4%)
2 (40%)
0 (0%)
5 (100%)
Randomized
136 (96%) 103 (76%) 51 (37%)
126 (93%)
Nonrandomized
1 (1%)
1 (100%)
0 (0%)
1 (100%)
Blinding
Double-Blinded
135 (95%) 102 (76%) 51 (37%)
125 (92%)
Open-Label
7 (5%)
4 (57%)
0 (0%)
7 (100%)
Comparators
Placebo Only
94 (66%)
70 (74%)
42 (45%)
86 (91%)
Active Comparator
Only
8 (6%)
5 (63%)
1 (13%)
7 (88%)
Placebo and Active
Comparator
29 (20%)
23 (79%)
6 (21%)
28 (97%)
Lower-Dose Comparator Only
4 (3%)
4 (100%)
2 (50%)
4 (100%)
No comparator
7 (5%)
4 (57%)
0 (0%)
7 (100%)
Note: FDAAA=Food and Drug Administration Amendments Act

Table 3. Publication and Publication-FDA Agreement of Trials Supporting FDA
Approval of NDAs with Neuropsychiatric Indications with Positive, Equivocal, and
Negative Results.

Pre-FDAAA

Post-FDAAA

FDA Interpretation of the
Trial Results, No. (%)

FDA Interpretation of the Trial Results, No. (%)
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Pub-FDA Interpretation
Agree
Pub-FDA Interpretation
Conflict
Not published

Positive
(n=72)

Equivocal
(n=16)

Negative
(n=13)

Positive
(n=35)

Equivocal
(n=1)

Negative
(n=5)

72 (100%)

9 (56%)

3
(23%)

35 (100%)

0 (0%)

5
(100%)

0 (0%)

5 (31%)

2
(13%)

0 (0%)

1 (100%)

0 (0%)

0 (0%)

2 (13%)

8
(62%)

0 (0%)

0 (0%)

0 (0%)

Notes: Trials were classified as positive, negative, or equivocal based on the FDA’s
interpretation of the results. Published interpretation of the trial with the FDA’s
interpretation for each trial. The two were considered in agreement if the interpretations
were both categorized as positive, negative or equivocal, and no major contradictions
existed between the two statements. Negative and equivocal trials were combined into a
single group as non-positive trials when calculating publication bias.
Box 1 Examples of Trials Published with Interpretations Disagreeing with the
Interpretations of the FDA medical reviewers
FDA and Published Interpretations Not in Agreement
Example #1
Trial ID: Droxidopa (Northera) 301
FDAAA Status: Post-FDAAA
Sponsor: Chelsea Therapeutics
FDA interpretation: Equivocal. "These results were considered to be implausible, and quite
remarkable, different from all other data....1) If data from Site 507 were deemed acceptable, that
would mean that the dossier included a single positive study. But with only 1 positive study and
one site disproportionately responsible for the favorable treatment effect, the data would not
constitute sufficient evidence of efficacy upon which to base an approval action. 2) If data from
Site 507 were deemed inadmissible, then Study 301 was not positive; none of the studies were
positive.” (83)
Published interpretation: Positive. “"In patients with symptomatic nOH, droxidopa improved
symptoms and symptom impact on daily activities, with an associated increase in standing
systolic BP, and was generally well tolerated published the analysis per protocol.” (84)
Example of Contradicting Interpretation #2
Trial ID: Milnacipran Hydrochloride (Savella) 02
FDAAA Status: Pre-FDAAA
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Sponsor: Forest Research Institute and Cypress Bioscience
FDA interpretation: Negative “[The] analysis of the ‘pain only’ responders does not indicate
that there is a significant effect of MLN (Savella) on pain…. (treatment effect) was driven by
the patient global response outcome rather than the pain or function outcome…when studied in
isolation, statistically significant treatment effects for pain and function were not demonstrated.”

(82)

Published interpretation: Positive. “both doses (100 and 200 mg/d) were associated with
significant improvements in pain and other symptoms.” (81)
Example of Contradicting Interpretation #3
Trial ID: Rufinamide (Banzel) AE/ET1
FDAAA Status: Pre-FDAAA
Sponsor: Novartis
FDA interpretation: Equivocal. FDA conclusion in summary review “Dr. Siddiqui noted that
the sponsor had included the placebo group in its dose response analyses. Further, he noted that
the dose groups were coded inappropriately (non-proportional to the actual dose). When the
doses were coded proportionally to the actual dose in his dose-response analysis, and placebo
was excluded, the p-value for the dose response slope was 0.086, implying none of the dose
differed materially.” (85)
Published interpretation: Positive. The author concluded in the abstract of the publication that
“in the linear trend of dose response for seizure frequency per 28 days in the double-blind
treatment phase was statistically significant in favor of rufinamide (p=0.003).” (86)
Example of Contradicting Interpretation #4
Trial ID: Milnacipran Hydrochloride (Savella) 031
FDAAA Status: Pre-FDAAA
Sponsor: Forest Research Institute and Cypress Bioscience
FDA interpretation: Equivocal. The FDA medical reviewer in more than one places in the
review emphasized that this trial fail to demonstrate effect as far as pain is concerned: “analysis
of the ‘pain only’ responders does not indicate that there is a significant effect of MLN(Savella)
on pain” and the treatment effect is “driven by the patient global response outcome rather than
the pain or function outcome, when studied in isolation, statistically significant treatment effects
for pain and function were not demonstrated”. In the risk benefit section of the summary review,
the FDA again stated that "an unusual finding in this application is that, while the product
appears to be effective when measured according to a prespecified responder definition, the
results on the individual components of that responder definition, pain, function and a patient
global evaluation, were not consistently statistically significant in the post-hoc analyses
performed by the clinical/statistical review team. In particularly, the dominant feature of FM is
pain and the results of the team's analyses of the individual pain endpoints did not demonstrate a
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statistically significant treatment effect for Savella (milnacipran), on the pain endpoint in either
of the clinical trials." (82)
Published interpretation: Positive. For trial 02 of milnacipran (Savella), the author of the
publication concluded in the abstract that “both doses (100 and 200 mg/d) were associated with
significant improvements in pain and other symptoms.” (87)
Example of Contradicting Interpretation #5
Trial ID: Iloperidone (Fanapt) 3000
FDAAA Status: Pre-FDAAA
Sponsor: Vanda Pharmaceuticals Inc
FDA interpretation: Negative. “Thus, either approach to defining the sample for this study
(whether it's FDA preferred or sponsor preferred) yields a negative result for iloperidone. With
the sponsor's preferred analysis including all randomized patients, the superiority of haloperidol
(active comparator) over the primary iloperidone (study drug) group (8+12mg) is statistically
significant. This study, therefore, provides no support for iloperidone (study drug) but does
suggest the statistically significant superiority of haloperidol (active control) over iloperidone
(study drug).” FDA reviewer also pointed out that the protocol of 3000 specified that no
comparison of individual doses against place can be done unless the combined group
12mg+8mg are shown to be significant, since the combined dose was not significant, then no
individual dose comparison can be done, and the study is negative.” (88)
Published interpretation: Positive. Publication concluded that 3000, 3004 and 3005 are all
positive. The positive conclusion for 3000 was partially supported by comparing the outcomes
of individual doses against placebo, a practice not supported by the protocol as pointed out the
FDA reviewer Publication also did not comment on the fact that the study drug was less
effective than the active control. Also, in the abstract session is the mentioning of other analysis.
"Additional analysis in patients who received active treatment for at least 2 weeks indicated
comparable efficacy score reductions at 6 weeks for patients receiving iloperidone 20 to 24
mg/d versus those receiving haloperidol or risperidone". The publication stated, at the end of the
abstract that "These trials indicate that iloperidone is effective for the treatment of
schizophrenia." (89)
Example of Contradicting Interpretation #6
Trial ID: Iloperidone (Fanapt) 3004
FDAAA Status: Pre-FDAAA
Sponsor: Vanda Pharmaceuticals Inc
FDA interpretation: Equivocal. "….... we still do not find this study an acceptable source of
evidence. Although the results for both dose groups in the all-randomized patients’ analysis are
positive, there is a striking difference in outcomes for the schizophrenic (intended indication)
and the schizoaffective (not intended indication) subgroups. The analysis focusing only on the
schizophrenic subgroup is not even close to positive for either dose group (p=0.306 for 1016mg/day and p=0.581 for 4-8mg/day).” Following this conclusion, the FDA reviewer stated " I
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think the data for that trial are fatally pathological, and one cannot reasonably pool data from the
schizophrenic and schizoaffective subgroups. It is not that I fundamentally object to polling data
from schizophrenic and schizoaffective patients (we have accepted this approach many times in
the past), but for this study, where the positive findings in the schizoaffective patients is by the
sponsor's own admission an 'anomaly,' there is no justification for such a pooling. Thus, I find
this study uninterpretable.” (88)
Published interpretation: Positive. Same as 3000. "These trials indicate that iloperidone is
effective for the treatment of schizophrenia." (89)
Example of Contradicting Interpretation #7
Trial ID: Iloperidone (Fanapt) 3005
FDAAA Status: Pre-FDAAA
Sponsor: Vanda Pharmaceuticals Inc
FDA interpretation: Equivocal. FDA noted that” the effect size observed in Study 3005 was
greater in active control than in both doses of iloperidone”. And that” the observation in study
3005 that the positive effect for iloperidone over placebo was coming almost entirely from the
non-US sites.” The reviewer, in summarizing the findings in study 3005, pointed out that stated
that the data collected from the US sites for study 3005 were uninterpretable I am persuaded by
the sponsor's argument that the lack of efficacy in the US sites for study 3005 should not rule
out this study as a source of evidence. As they point out, risperidone also failed in the US sites,
and thus, data from these sites is simply uninterpretable.” The conclusion of the FDA was “For
study 3005, only the analysis focused on the schizophrenic subgroup shows superiority of
iloperidone over placebo. In the sponsor's preferred analysis, iloperidone fails to show
superiority to placebo and, at the same time, risperidone appears to be statistically significantly
superior to iloperidone.” (88)
Published interpretation: Positive. Publication concluded that one of the doses in study 3005,
20–24 mg/d [P = 0.010]). "Active controls were also significantly more effective than placebo in
each trial, thus validating the trials... These trials indicate that iloperidone is effective for the
treatment of schizophrenia." No comparison was drawn between the active control with
iloperidone. No statement was made regarding the data from the US study sites were
uninterpretable.” (89)
Example of Contradicting Interpretation #8
Trial ID: Dalfampridine (Ampyra)
202
FDAAA Status: Pre-FDAAA
Sponsor: Acorda Therapeutics Inc
FDA interpretation: Negative. "There were no statistically significant differences between any
dose and placebo. Independent analyses by Dr. Joo-Yeon Lee of Pharmacometrics has shown no
dose response in the range studied for the percent change from baseline in walking speed.” (90)
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Published interpretation: Equivocal. “This phase 2 study suggests that a subgroup of patients,
when treated with fampridine, experiences a clinically relevant improvement in walking ability,
which is sustained for at least 14 weeks.” (91)

Publication Bias
Pre-FDAAA, positive trials were more likely to be published (RR=1.52; 95%
Confidence Interval [CI]=1.17-1.99; P=0.002) and published without misleading
interpretations (RR=2.47; Cl=1.57-3.73; p<0.001) than those with non-positive results. In
contrast, post-FDAAA, positive trials were equally likely to have been published (RR=1;
Cl=1-1, p=NA) and published without misleading interpretations (RR=1.20; Cl=0.841.72; p=0.30). The likelihood of publication bias pre-FDAAA vs. post-FDAAA was
greater for publication of positive vs. non-positive trials (RRR=1.52; Cl=1.16-1.99;
p=0.002) and for publication without misleading interpretations (RRR=2.06, Cl=1.173.61, p=0.01).
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Discussion

Study Findings & Prior literature
In this retrospective cohort study of 142 trials supporting the approval of 37
neuropsychiatric therapeutics approved by the FDA between 2005 and 2014, postFDAAA trials were uniformly registered, reported results, published, and published
without misleading interpretations. As compared to pre-FDAAA trials, proportions of
trials that were registered and reporting results on ClinicalTrials.gov were significantly
higher and the degree of publication bias was lower. Our results suggest that FDAAA
likely contributed to improving the registration, results reporting, and publication of
clinical trials supporting FDA approval of new drugs used to treat neuropsychiatric
indications, although other factors may also have been in play.
Prior work examining similar clinical trials supporting FDA approval of new drugs
in 2012, many of which were completed before FDAAA as enacted, found 57% were
registered and 20% reported results on ClinicalTrials.gov. (41) Among trials supporting
approval of neuropsychiatric drugs, we found similar rates among pre-FDAAA trials,
63% and 10%, but also show that among post-FDAAA trials, 100% were registered and
reported results. A study involving trials supporting FDA approval of cardiovascular and
diabetic drugs showed a similar association between FDAAA and trial registration and
results reporting. (80)
As discussed previously, earlier studies have consistently demonstrated significant
publication bias: positive trials are more likely to be published and published accurately
or completely than non-positive trials. In our study, such publication bias was observed
only among trials that were completed prior to FDAAA enactment, but not afterwards. In
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addition, overall rates of clinical trial publication were quite high, challenging the
assumption that selective publication is worse among clinical trials of neuropsychiatric
drugs than for other types of drugs. Our findings have important implications for
understanding the impact of FDAAA, for developing future strategies to improve
selective publication and outcome reporting more broadly, and for the practice of
evidence-based medicine.

Implication for Understanding the Impact of FDAAA
There is likely a causal relationship between the enactment of FDAAA and the
improved rates of registration and results reporting given the strength of the association,
consistency of the association across different types of trials, existence of a temporal
relationship, and high degree of plausibility. When we examined the relationship between
FDAAA status with registration status and the relationship between FDAAA status with
results reporting status using the two tailed Fisher Exact test, the p-Value was less than
0.001 in both cases. Studies evaluating trials for cardiovascular and diabetic drugs
showed the similar results. Considering that FDAAA explicitly required registration and
results reporting and has the power to fine the sponsors $11,569 for each day a trial
remains unreported following a 30-day notification period, it is reasonable to anticipate
that there is high degree of compliance for trials that were initiated after the FDAAA
enactment. Other changes might also be contributory. For example, trials involving
patients with serious and life threatening illnesses and pediadiatric patients were required
to register according to FDAMA1997 and according to guidelines issued by the FDA for
the pharmaceutical industry practice as early as 2004. (92). The ICMJE recommendation
issued in 2004 might also have had a small impact on trial registration, specifically
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prospective trial registration. However, as previously discussed, only the 11 members of
ICMJE were required to comply with ICMJE, while other journals follow the
recommendation on a voluntary bassis. When surveyed, editors were willing to consider
the publication of unregistered trials due to many factors: “not wanting to lose out to rival
journals, not wanting to reject otherwise sound articles or submissions from developing
countries, and perceptions that such policies were not relevant to all journals.” (93)
The impact of FDAAA on reducing publication bias is less clear because FDAAA
does not regulate medical journals directly. Our results at least provided a positive
outlook. Post-FDAAA trials, regardless of the results, were all published. Publication
bias was not detectable among the post-FDAAA trials and represents a significant
improvement compared to the pre-FDAAA trials.

Implications for Future Policy Development
FDAAA applies only to trials of medical products regulated by the FDA. But the
practice of medicine includes not only the use of medical products to improve patient
outcomes, but also behavioral, surgical and other procedural interventions, as well as
health system interventions. To ensure that the medical literature is as unbiased and
representative as is possible, rules and regulations like FDAAA, which mandate
registration and results reporting in a publicly accessible database but also apply to all
clinical research and health system studies, may be an effective strategy to promote
comprehensive registration, results reporting, and publication.

Implications for the Practice of Medicine
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The sponsors and investigators have published all of the Post-FDAAA clinical
trials supporting the FDA’s decision to approve new drugs treating neurologic and
psychiatric conditions and there were no negative trials misleadingly published to
encourage positive interpretation. Evidence-based practice regarding the use of these
drugs will be less affected by publication bias. However, it is uncertain whether this will
improve the practice of medicine for several reasons. One, the “effective publication
rate,” as perceived by clinicians and patients, may be lower because the publications for
some trials were difficult to locate and were only found using specific trial data in
multiple search engines. Two, the pharmaceutical companys, supported usually by large
marketing departments have other ways to “advertise” their expensively made products,
to incentivize physicians to prescribe the newer and more expensive drugs over the older
or cheaper drugs. Lastly, it is unclear that EBM is itself the appropriate framework for
medical decision making. The chasm between the RCT-based formula to providing care
to patients, each with their unique circumstances in resource-constrained environments, is
vast.

Limitations
Several factors should be considered in the interpretation of our findings. First, our
study is cross-sectional and can only establish associations, not causality. Other reasons
beyond FDAAA, including academic advocacy for clinical trial data transparency, may
have accounted for trial sponsors’ and investigators’ decision to register, report results
and publish the findings of the clinical trials. More studies are needed to disentangle the
impact of FDAAA on clinical trial registration, results reporting, and publication from
other factors that may have contributed to these trends, especially the ICMJE clinical trial
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registration policy, although it’s not clear that this policy would impact either results
reporting or publication. Second, we limited our search of trial registration to
ClinicalTrials.gov. It is possible that trials conducted pre-FDAAA used other registers.
Third, for trials determined to be unregistered or unpublished, we did not contact sponsor
companies for confirmation. Fourth, our sample is limited to phase II and III trials
supporting neuropsychiatric drugs and the sample size of post-FDAAA trials, at 41, is
relatively small. Fifth, our study was focused on pre-marketing phase II and III trials
evaluating neuropsychiatric drugs successfully approved by the FDA. Our findings may
not be generalized to phase I and phase IV post marketing trials, trials evaluating drugs
that were not approved by the FDA, as well as trials for other types of drugs for which
the registration and publication have yet to be characterized. Finally, our study was
focused on the reporting and publication of trials’ primary results and did not examine
reporting or publication of secondary and safety outcomes.

Conclusions
For clinical trials supporting the FDA approval of new drugs for
neuropsychiatric indications, the proportions of trials that were registered and reporting
results on ClinicalTrials.gov were significantly higher and publication bias was
significantly lower after the passage of FDAAA in 2007, suggesting that FDAAA likely
contributed to the reduction of selective registration and results reporting and to
mitigating publication bias. These findings have important implications for understanding
the potential impact of FDAAA, along with other initiatives that may have improved
research reporting, and for developing future strategies to improve selective publication
and outcome reporting more broadly.
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Figures, Titles, and Legends
Figure 1. Identification of Trials Reviewed by the FDA for New Drug Applications with
Neuropsychiatric Indications, 2005-2014

Legend: Flow chart depicting the process of selecting efficacy trials reviewed by the
FDA for the approval of new drug with neuropsychiatric indicatioons between 20052014. Trials can be excluded for satisfying one or more exclusion criteria.
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Figure 2 Registration and Results Reporting Status of Trials Supporting FDA Indications
by FDAAA applicability, 2005-2014
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Legend: Post-FDAAA trials were significantly more likely to be registered (100% vs
64%; P<0.001) and report results (100% vs 10%; P<0.001) than pre-FDAAA. Outcomes
were compared by two-tailed Fisher Exact tests.
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Post-FDAAA
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Figure 3. Publication Status and Publication-FDA Agreement of Neuropsychiatric Trials
by FDAAA applicability and by Trial Results
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Legend: Overall, more Post-FDAAA trials were published (100% vs 90%; P=0.06) and
the publication were in agreement with the FDA’s interpretation (98% vs. 93%; P=0.28),
but neither the outcomes were significant. When stratified by results, trials with positive
were all published during both pre- (72 of 72) and post-FDAAA (35 of 35). When trials
with negative results were examined in isolation, the publication rate was significantly
higher after FDAAA as compared to before (5 of 5 vs 5 of 13; P=0.04). There were not
enough equivocal trials to draw comparison. All comparisons were based on two-tailed
Fisher Exact tests.

